You are here
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
NEWARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced the early completion of enrollment in a Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic steatohepatitis (NASH). The company expects to report 12-week topline results on changes in liver fat and key biochemical parameters in the second quarter.
Tuesday, February 19, 2019 - 08:00